Is Growing Focus On CAR-T Data And CARVYKTI Orders Reframing Legend Biotech’s (LEGN) Investment Story?

Simply Wall St.05-02 21:35

In late April 2026, Legend Biotech presented at the Cell & Gene Meeting on the Mediterranean in Rome and scheduled a May 12 investor call to discuss its first quarter 2026 results. Analyst commentary ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2632676397?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-05-02 21:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2632676397","market":"us","top_or_hot":-1,"title":"Is Growing Focus On CAR-T Data And CARVYKTI Orders Reframing Legend Biotech’s (LEGN) Investment Story?","media":"Simply Wall St.","content":"<div>\n<p>In late April 2026, Legend Biotech presented at the Cell & Gene Meeting on the Mediterranean in Rome and scheduled a May 12 investor call to discuss its first quarter 2026 results. Analyst commentary ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-legn/legend-biotech/news/is-growing-focus-on-car-t-data-and-carvykti-orders-reframing\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Growing Focus On CAR-T Data And CARVYKTI Orders Reframing Legend Biotech’s (LEGN) Investment Story?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Growing Focus On CAR-T Data And CARVYKTI Orders Reframing Legend Biotech’s (LEGN) Investment Story?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-02 21:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-legn/legend-biotech/news/is-growing-focus-on-car-t-data-and-carvykti-orders-reframing><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In late April 2026, Legend Biotech presented at the Cell & Gene Meeting on the Mediterranean in Rome and scheduled a May 12 investor call to discuss its first quarter 2026 results. Analyst commentary ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-legn/legend-biotech/news/is-growing-focus-on-car-t-data-and-carvykti-orders-reframing\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-legn/legend-biotech/news/is-growing-focus-on-car-t-data-and-carvykti-orders-reframing","article_id":"2632676397","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-legn/legend-biotech/news/is-growing-focus-on-car-t-data-and-carvykti-orders-reframing","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2632676397","pubTimestamp":1777728926,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In late April 2026, Legend Biotech presented at the Cell & Gene Meeting on the Mediterranean in Rome and scheduled a May 12 investor call to discuss its first quarter 2026 results.\nAnalyst commentary has zeroed in on Legend’s CAR-T pipeline and CARVYKTI order book strength, with attention building around imminent clinical data readouts and medical meeting updates.\nNext, we’ll examine how expectations around upcoming CAR-T clinical data could influence Legend Biotech’s existing investment...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"对CAR-T数据和CARVYKTI订单的日益关注是否正在重塑传奇生物(LEGN)的投资故事？","themeId":null,"isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/539cf4ad3cc251a313d9486e3a155749","symbols_score_info":{"XBI":1.5,"AIPO":0.73,"LEGN":1.5,"AGIX":0.62,"AIYY":0.6,"CAR":1.5,"ARTY":0.62,"CHAT":0.62,"AI":0.62},"content_text":"In late April 2026, Legend Biotech presented at the Cell & Gene Meeting on the Mediterranean in Rome and scheduled a May 12 investor call to discuss its first quarter 2026 results. Analyst commentary has zeroed in on Legend’s CAR-T pipeline and CARVYKTI order book strength, with attention building around imminent clinical data readouts and medical meeting updates. Next, we’ll examine how expectations around upcoming CAR-T clinical data could influence Legend Biotech’s existing investment narrative. Capitalize on the AI infrastructure supercycle with our selection of the 37 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.AdvertisementLegend Biotech Investment Narrative RecapTo own Legend Biotech, you need to believe that CARVYKTI can remain a meaningful commercial franchise while the broader CAR T pipeline matures into additional revenue streams. The latest conference appearance and upcoming May 12 earnings call mainly reinforce the existing focus on near term clinical readouts as the key catalyst, while the biggest risk still centers on CARVYKTI concentration and how any shift in orders or safety profile could affect the story. The H.C. Wainwright commentary tying strong CARVYKTI order book trends to “imminent” clinical and medical meeting data is the most relevant update here, because it directly links current commercial demand with expectations for new CAR T results. That combination keeps attention squarely on how upcoming trial readouts, including in vivo CD19/CD20 programs, could either support Legend’s diversification ambitions or underline how dependent the company still is on one product. Yet beneath the optimism around CARVYKTI orders, investors should be aware that concentrated reliance on a single therapy means... Read the full narrative on Legend Biotech (it's free!)Legend Biotech's narrative projects $2.1 billion revenue and $501.1 million earnings by 2029. This requires 27.3% yearly revenue growth and an earnings increase of about $798 million from -$296.8 million today.Uncover how Legend Biotech's forecasts yield a $57.24 fair value, a 143% upside to its current price.Exploring Other PerspectivesLEGN 1-Year Stock Price Chart Compared with consensus, the lowest ranked analysts paint a much harsher picture, assuming revenue of about US$1.6 billion and earnings of only US$69.7 million by 2029, so if you worry about pricing pressure and CARVYKTI concentration despite the latest CAR T data buzz, it is worth seeing how differently other investors weigh these possibilities.Explore 5 other fair value estimates on Legend Biotech - why the stock might be worth over 5x more than the current price!Reach Your Own ConclusionDisagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your Legend Biotech research is our analysis highlighting 2 key rewards that could impact your investment decision.Our free Legend Biotech research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Legend Biotech's overall financial health at a glance.Seeking Other Investments?Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:Uncover the next big thing with 24 elite penny stocks that balance risk and reward.Find 51 companies with promising cash flow potential yet trading below their fair value.The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2632676397","isCrawlerRequest":true}